Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight

• Published in: Journal of nanobiotechnology 2021-04, Vol.19 (1), p.106-51, Article 106
• Main Authors: Jamshaid, Humzah, Din, Fakhar Ud, Khan, Gul Majid
• Format: Article
• Language: English
• Subjects: Adjuvants; Antigen presentation; Antigens; Barriers; Care and treatment; Chemotherapy; Cutaneous leishmaniasis; Cytotoxicity; Drug delivery; Drug delivery systems; Drugs; Epidemics; Immune system; Immunization; Immunosuppressive agents; Infections; Leishmaniasis; Lymphocytes T; Macrophages; Mammals; Mannosylated thiolated nanosystem; Methods; Morbidity; Nano-adjuvants; Nano-DDS; Nanomedicine; Nanotechnology; Parasite resistance; Parasites; Parasitic diseases; Pharmacokinetics; Poverty; Review; Skin; Splenomegaly; Toxicity; Tropical diseases; Vaccines; Vector-borne diseases
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-021-00853-0

As a neglected tropical disease, Leishmaniasis is significantly instigating morbidity and mortality across the globe. Its clinical spectrum varies from ulcerative cutaneous lesions to systemic immersion causing hyperthermic hepato-splenomegaly. Curbing leishmanial parasite is toughly attributable to the myriad obstacles in existing chemotherapy and immunization. Since the 1990s, extensive research has been conducted for ameliorating disease prognosis, by resolving certain obstacles of conventional therapeutics viz. poor efficacy, systemic toxicity, inadequate drug accumulation inside the macrophage, scarce antigenic presentation to body's immune cells, protracted length and cost of the treatment. Mentioned hurdles can be restricted by designing nano-drug delivery system (nano-DDS) of extant anti-leishmanials, phyto-nano-DDS, surface modified-mannosylated and thiolated nano-DDS. Likewise, antigen delivery with co-transportation of suitable adjuvants would be achievable through nano-vaccines. In the past decade, researchers have engineered nano-DDS to improve the safety profile of existing drugs by restricting their release parameters. Polymerically-derived nano-DDS were found as a suitable option for oral delivery as well as SLNs due to pharmacokinetic re-modeling of drugs. Mannosylated nano-DDS have upgraded macrophage internalizing of nanosystem and the entrapped drug, provided with minimal toxicity. Cutaneous Leishmaniasis (CL) was tackling by the utilization of nano-DDS designed for topical delivery including niosomes, liposomes, and transfersomes. Transfersomes, however, appears to be superior for this purpose. The nanotechnology-based solution to prevent parasitic resistance is the use of Thiolated drug-loaded and multiple drugs loaded nano-DDS. These surfaces amended nano-DDS possess augmented IC values in comparison to conventional drugs and un-modified nano-DDS. Phyto-nano-DDS, another obscure horizon, have also been evaluated for their anti-leishmanial response, however, more intense assessment is a prerequisite. Impoverished Cytotoxic T-cells response followed by Leishmanial antigen proteins delivery have also been vanquished using nano-adjuvants. The eminence of nano-DDS for curtailment of anti-leishmanial chemotherapy and immunization associated challenges are extensively summed up in this review. This expedited approach is ameliorating the Leishmaniasis management successfully. Alongside, total to partial eradication of this disease can be sou